The New Pain Drug That Doesn't Require a Needle Is Changing Chronic Pain Treatment

A new class of oral non-opioid pain drugs is in late-stage trials. Here is the mechanism, the clinical results, and when they might reach patients who have exhausted current options.

Chronic pain — pain lasting more than three months, often without clear resolution pathway — affects approximately 20-25 percent of the adult population in developed countries. Its treatment has been one of medicine's most persistent failures: opioids work but create addiction; NSAIDs work but cause gastrointestinal and cardiovascular harm with long-term use; antidepressants and anticonvulsants work for some pain types but require careful titration and have side effect profiles that many patients find intolerable.

The new class of sodium channel antagonists that suzetrigine (Journavax) belongs to has opened a pharmacological space that was hypothesised but until recently unoccupied: oral medications that selectively block pain transmission at the peripheral nervous system without central nervous system effects. Suzetrigine targets Nav1.8, one of nine sodium channel subtypes. Additional compounds targeting Nav1.7 — a channel whose role in pain conduction is established by the rare genetic mutations that cause people to be born unable to feel pain — are in Phase 2 and Phase 3 trials from multiple pharmaceutical companies.

The Nav1.7 connection is particularly promising for specific chronic pain conditions. Patients with inherited erythromelalgia — a condition caused by gain-of-function Nav1.7 mutations that produces severe burning pain — have shown dramatic improvement in trials of Nav1.7 inhibitors. Small fibre neuropathy, diabetic neuropathy, and other conditions mediated by abnormal Nav1.7 activity are the conditions that Nav1.7 inhibitors may specifically address.

For the patient perspective: chronic pain's burden extends beyond the physical. The Global Wellness Summit's analysis notes that chronic pain patients frequently describe their condition as having stolen their identity — their ability to work, to maintain relationships, to participate in activities that define who they are. A safe, oral, effective treatment for neuropathic chronic pain would be one of medicine's most significant quality-of-life improvements for a population whose suffering has been inadequately addressed.